In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Balchem Corp (NASDAQ: BCPC), with a price target of $140. The company’s shares closed on Friday at $96.20.
Selvaraju wrote:
“Valuation methodology, risks and uncertainties. We utilize a comparable universe-derived P/E multiple approach to determine our price target. Applying a roughly 46x P/E multiple to our 2019 diluted EPS of $3.03, we derive a price objective of $140 per share.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -7.6% and a 28.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Synergy Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Balchem Corp with a $117.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $117.79 and a one-year low of $70.23. Currently, Balchem Corp has an average volume of 96.35K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Balchem Corp. engages in the development, manufacture, and marketing of specialty performance ingredients and products. It operates through the following segments: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products, and Industrial Products.
